Posted by Michael Wonder on 01 Apr 2025
Highlights from the 24-27 March 2025 CHMP meeting
28 March 2025 - The EMA’s CHMP recommended five medicines for approval at its March 2025 meeting.
The committee recommended granting a marketing authorisation for Xoanacyl (ferric citrate coordination complex), indicated for the treatment of concomitant hyperphosphataemia and iron deficiency in adults with chronic kidney disease.
